Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purinostat mesylate plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma
ChiCTR2500098210Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of purinostat, pomalidomide and dexamethasone in multiple myeloma (MM) (10 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective response rate, Maximum tolerated dose and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
purinostatpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500098210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098210.